RESULTS = "[
    {
        "safetyreportversion": "1",
        "safetyreportid": "23325025",
        "primarysourcecountry": "US",
        "occurcountry": "US",
        "transmissiondateformat": "102",
        "transmissiondate": "20240110",
        "reporttype": "1",
        "serious": "1",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "1",
        "receivedateformat": "102",
        "receivedate": "20231221",
        "receiptdateformat": "102",
        "receiptdate": "20231221",
        "fulfillexpeditecriteria": "1",
        "companynumb": "US-BRISTOL-MYERS SQUIBB COMPANY-2023-183468",
        "primarysource": {
            "reportercountry": "US",
            "qualification": "5"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "patientonsetage": "61",
            "patientonsetageunit": "801",
            "patientagegroup": "5",
            "patientsex": "2",
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Hepatic enzyme abnormal",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "ZEPOSIA",
                    "drugbatchnumb": "Unknown",
                    "drugauthorizationnumb": "209899",
                    "drugstructuredosagenumb": "0.92",
                    "drugstructuredosageunit": "003",
                    "drugseparatedosagenumb": "1",
                    "drugintervaldosageunitnumb": "1",
                    "drugintervaldosagedefinition": "804",
                    "drugdosageform": "Capsule",
                    "drugadministrationroute": "048",
                    "drugindication": "Multiple sclerosis",
                    "actiondrug": "1",
                    "activesubstance": {
                        "activesubstancename": "OZANIMOD HYDROCHLORIDE"
                    },
                    "openfda": {
                        "application_number": [
                            "NDA209899"
                        ],
                        "brand_name": [
                            "ZEPOSIA 7-DAY STARTER PACK",
                            "ZEPOSIA",
                            "ZEPOSIA STARTER KIT"
                        ],
                        "generic_name": [
                            "OZANIMOD HYDROCHLORIDE"
                        ],
                        "manufacturer_name": [
                            "Celgene Corporation"
                        ],
                        "product_ndc": [
                            "59572-810",
                            "59572-820",
                            "59572-890"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "rxcui": [
                            "2288406",
                            "2288412",
                            "2288414",
                            "2288416",
                            "2288418",
                            "2288420",
                            "2288430",
                            "2288431",
                            "2288432",
                            "2288433",
                            "2642213",
                            "2642214"
                        ],
                        "spl_id": [
                            "695f45ec-a0d4-42d7-8e43-9d54fe330792"
                        ],
                        "spl_set_id": [
                            "93ce2fab-edfb-4804-8074-963071de51e4"
                        ],
                        "package_ndc": [
                            "59572-820-30",
                            "59572-820-97",
                            "59572-810-07",
                            "59572-810-97",
                            "59572-890-91",
                            "59572-890-97",
                            "59572-890-28",
                            "59572-890-98"
                        ],
                        "unii": [
                            "3UPR33JAAM"
                        ],
                        "route": [
                            "ORAL"
                        ],
                        "substance_name": [
                            "OZANIMOD HYDROCHLORIDE"
                        ]
                    }
                }
            ]
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23325430",
        "primarysourcecountry": "US",
        "occurcountry": "US",
        "transmissiondateformat": "102",
        "transmissiondate": "20240110",
        "reporttype": "1",
        "serious": "2",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "2",
        "receivedateformat": "102",
        "receivedate": "20231221",
        "receiptdateformat": "102",
        "receiptdate": "20231221",
        "fulfillexpeditecriteria": "2",
        "companynumb": "US-AMGEN-USASP2023220393",
        "duplicate": "1",
        "reportduplicate": {
            "duplicatesource": "AMGEN INC",
            "duplicatenumb": "US-AMGEN INC-23-0333257-SR-01"
        },
        "primarysource": {
            "reportercountry": "US",
            "qualification": "3"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Needle issue",
                    "reactionoutcome": "6"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Poor quality device used",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "NEULASTA",
                    "drugauthorizationnumb": "125031",
                    "drugstructuredosagenumb": "6",
                    "drugstructuredosageunit": "003",
                    "drugdosagetext": "6 MILLIGRAM",
                    "drugdosageform": "Solution for injection",
                    "drugadministrationroute": "065",
                    "drugindication": "Product used for unknown indication",
                    "actiondrug": "6",
                    "drugadditional": "4",
                    "activesubstance": {
                        "activesubstancename": "PEGFILGRASTIM"
                    },
                    "openfda": {
                        "application_number": [
                            "BLA125031"
                        ],
                        "brand_name": [
                            "NEULASTA"
                        ],
                        "generic_name": [
                            "PEGFILGRASTIM"
                        ],
                        "manufacturer_name": [
                            "Amgen Inc"
                        ],
                        "product_ndc": [
                            "55513-190",
                            "55513-192"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "route": [
                            "SUBCUTANEOUS"
                        ],
                        "substance_name": [
                            "PEGFILGRASTIM"
                        ],
                        "rxcui": [
                            "727539",
                            "727542",
                            "2549331",
                            "2549333"
                        ],
                        "spl_id": [
                            "50374606-0a76-45df-8b19-8323cc511e87"
                        ],
                        "spl_set_id": [
                            "fdfe5d72-6b80-435a-afa4-c5d74dd852ce"
                        ],
                        "package_ndc": [
                            "55513-192-01",
                            "55513-190-01"
                        ],
                        "nui": [
                            "M0024696",
                            "N0000009451",
                            "N0000175666"
                        ],
                        "pharm_class_cs": [
                            "Granulocyte Colony-Stimulating Factor [CS]"
                        ],
                        "pharm_class_pe": [
                            "Increased Myeloid Cell Production [PE]"
                        ],
                        "pharm_class_epc": [
                            "Leukocyte Growth Factor [EPC]"
                        ],
                        "unii": [
                            "3A58010674"
                        ]
                    }
                }
            ]
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23325698",
        "primarysourcecountry": "FR",
        "occurcountry": "FR",
        "transmissiondateformat": "102",
        "transmissiondate": "20240110",
        "reporttype": "1",
        "serious": "2",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "2",
        "receivedateformat": "102",
        "receivedate": "20231221",
        "receiptdateformat": "102",
        "receiptdate": "20231221",
        "fulfillexpeditecriteria": "5",
        "companynumb": "FR-JNJFOC-20231226920",
        "primarysource": {
            "reportercountry": "FR",
            "qualification": "2"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Device issue",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "PREZISTA",
                    "drugauthorizationnumb": "202895",
                    "drugdosagetext": "STRENGTH: UNKNOWN",
                    "drugdosageform": "Oral suspension",
                    "drugadministrationroute": "048",
                    "drugindication": "Product used for unknown indication",
                    "actiondrug": "5",
                    "drugadditional": "3",
                    "activesubstance": {
                        "activesubstancename": "DARUNAVIR ETHANOLATE"
                    },
                    "openfda": {
                        "application_number": [
                            "NDA021976",
                            "NDA202895"
                        ],
                        "brand_name": [
                            "PREZISTA"
                        ],
                        "generic_name": [
                            "DARUNAVIR"
                        ],
                        "manufacturer_name": [
                            "Janssen Products LP"
                        ],
                        "product_ndc": [
                            "59676-562",
                            "59676-563",
                            "59676-564",
                            "59676-566",
                            "59676-565"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "route": [
                            "ORAL"
                        ],
                        "substance_name": [
                            "DARUNAVIR ETHANOLATE"
                        ],
                        "rxcui": [
                            "670026",
                            "794610",
                            "831868",
                            "831870",
                            "850455",
                            "850457",
                            "1236628",
                            "1236632",
                            "1359269",
                            "1359271"
                        ],
                        "spl_id": [
                            "02fd607e-f780-dd47-e063-6394a90aad7d"
                        ],
                        "spl_set_id": [
                            "814301f9-c990-46a5-b481-2879a521a16f"
                        ],
                        "package_ndc": [
                            "59676-563-01",
                            "59676-564-01",
                            "59676-562-01",
                            "59676-566-30",
                            "59676-565-01"
                        ],
                        "unii": [
                            "33O78XF0BW"
                        ]
                    }
                }
            ]
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23072780",
        "primarysourcecountry": "US",
        "transmissiondateformat": "102",
        "transmissiondate": "20240110",
        "reporttype": "2",
        "serious": "1",
        "seriousnessdeath": "1",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "1",
        "receivedateformat": "102",
        "receivedate": "20231017",
        "receiptdateformat": "102",
        "receiptdate": "20231017",
        "fulfillexpeditecriteria": "1",
        "companynumb": "2023A233878",
        "duplicate": "1",
        "reportduplicate": [
            {
                "duplicatesource": "CVS/Caremark Specialty Pharmacy",
                "duplicatenumb": "1703"
            },
            {
                "duplicatesource": "MC USA",
                "duplicatenumb": "23US0086897"
            }
        ],
        "primarysource": {
            "reportercountry": "US",
            "qualification": "3"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "patientonsetage": "13153",
            "patientonsetageunit": "804",
            "patientsex": "2",
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Death",
                    "reactionoutcome": "5"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Underdose",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "LYNPARZA",
                    "drugauthorizationnumb": "208558",
                    "drugstructuredosagenumb": "100",
                    "drugstructuredosageunit": "003",
                    "drugseparatedosagenumb": "2",
                    "drugintervaldosageunitnumb": "1",
                    "drugintervaldosagedefinition": "804",
                    "drugcumulativedosagenumb": "194800",
                    "drugcumulativedosageunit": "003",
                    "drugadministrationroute": "048",
                    "drugindication": "Breast cancer female",
                    "drugstartdateformat": "610",
                    "drugstartdate": "202101",
                    "actiondrug": "5",
                    "drugadditional": "3",
                    "activesubstance": {
                        "activesubstancename": "OLAPARIB"
                    },
                    "openfda": {
                        "application_number": [
                            "NDA208558"
                        ],
                        "brand_name": [
                            "LYNPARZA"
                        ],
                        "generic_name": [
                            "OLAPARIB"
                        ],
                        "manufacturer_name": [
                            "AstraZeneca Pharmaceuticals LP"
                        ],
                        "product_ndc": [
                            "0310-0668",
                            "0310-0679"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "route": [
                            "ORAL"
                        ],
                        "substance_name": [
                            "OLAPARIB"
                        ],
                        "rxcui": [
                            "1942482",
                            "1942485",
                            "1942487",
                            "1942489"
                        ],
                        "spl_id": [
                            "5d1fb11d-00fa-48eb-b915-acf9ae26de79"
                        ],
                        "spl_set_id": [
                            "741ff3e3-dc1a-45a6-84e5-2481b27131aa"
                        ],
                        "package_ndc": [
                            "0310-0668-60",
                            "0310-0668-12",
                            "0310-0668-95",
                            "0310-0679-60",
                            "0310-0679-12",
                            "0310-0679-95"
                        ],
                        "nui": [
                            "N0000191623",
                            "N0000191622"
                        ],
                        "pharm_class_epc": [
                            "Poly(ADP-Ribose) Polymerase Inhibitor [EPC]"
                        ],
                        "pharm_class_moa": [
                            "Poly(ADP-Ribose) Polymerase Inhibitors [MoA]"
                        ],
                        "unii": [
                            "WOH1JD9AR8"
                        ]
                    }
                }
            ],
            "summary": {
                "narrativeincludeclinical": "CASE EVENT DATE: 20230907"
            }
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23073657",
        "primarysourcecountry": "GB",
        "transmissiondateformat": "102",
        "transmissiondate": "20240109",
        "reporttype": "1",
        "serious": "1",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "1",
        "receivedateformat": "102",
        "receivedate": "20231017",
        "receiptdateformat": "102",
        "receiptdate": "20231017",
        "fulfillexpeditecriteria": "1",
        "companynumb": "GB-MHRA-MED-202310031127293410-ZVSCG",
        "duplicate": "1",
        "reportduplicate": [
            {
                "duplicatesource": "ELECTRONICYCPROD",
                "duplicatenumb": "GB-MHRA-MED-202310031127293410-ZVSCG"
            },
            {
                "duplicatesource": "MHRAUK",
                "duplicatenumb": "GB-MHRA-ADR 28226207"
            }
        ],
        "primarysource": {
            "reportercountry": "GB",
            "qualification": "5"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "patientonsetage": "67",
            "patientonsetageunit": "801",
            "patientagegroup": "6",
            "patientweight": "85",
            "patientsex": "2",
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Malaise",
                    "reactionoutcome": "3"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Medication error",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "ATORVASTATIN",
                    "drugbatchnumb": "ASKU",
                    "drugauthorizationnumb": "205945",
                    "drugstructuredosagenumb": "50",
                    "drugstructuredosageunit": "003",
                    "drugseparatedosagenumb": "1",
                    "drugintervaldosageunitnumb": "1",
                    "drugintervaldosagedefinition": "804",
                    "drugdosagetext": "50 MG ONCE A DAY; ;",
                    "drugdosageform": "Tablet",
                    "drugindication": "Product used for unknown indication",
                    "drugstartdateformat": "102",
                    "drugstartdate": "20230926",
                    "actiondrug": "5",
                    "drugrecurreadministration": "3",
                    "drugadditional": "3",
                    "activesubstance": {
                        "activesubstancename": "ATORVASTATIN"
                    }
                },
                {
                    "drugcharacterization": "2",
                    "medicinalproduct": "COCODAMOL",
                    "drugbatchnumb": "ASKU",
                    "drugindication": "Arthritis",
                    "drugstartdateformat": "102",
                    "drugstartdate": "20230505",
                    "activesubstance": {
                        "activesubstancename": "ACETAMINOPHEN\\CODEINE PHOSPHATE"
                    }
                }
            ],
            "summary": {
                "narrativeincludeclinical": "CASE EVENT DATE: 20231003"
            }
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23074724",
        "primarysourcecountry": "US",
        "occurcountry": "US",
        "transmissiondateformat": "102",
        "transmissiondate": "20240110",
        "reporttype": "2",
        "serious": "1",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "1",
        "receivedateformat": "102",
        "receivedate": "20231017",
        "receiptdateformat": "102",
        "receiptdate": "20231017",
        "fulfillexpeditecriteria": "1",
        "companynumb": "US-ABBVIE-5453123",
        "primarysource": {
            "reportercountry": "US",
            "qualification": "5"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "patientonsetage": "49",
            "patientonsetageunit": "801",
            "patientsex": "2",
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Surgery",
                    "reactionoutcome": "6"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Heart rate increased",
                    "reactionoutcome": "1"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Nausea",
                    "reactionoutcome": "1"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Palpitations",
                    "reactionoutcome": "1"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Muscle spasms",
                    "reactionoutcome": "1"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Drug ineffective",
                    "reactionoutcome": "1"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "RINVOQ",
                    "drugbatchnumb": "Not Available",
                    "drugauthorizationnumb": "211675",
                    "drugstructuredosagenumb": "30",
                    "drugstructuredosageunit": "003",
                    "drugseparatedosagenumb": "1",
                    "drugintervaldosageunitnumb": "1",
                    "drugintervaldosagedefinition": "804",
                    "drugdosagetext": "FOR APPROXIMATELY THREE WEEKS",
                    "drugadministrationroute": "048",
                    "drugindication": "Dermatitis atopic",
                    "drugstartdateformat": "610",
                    "drugstartdate": "202210",
                    "drugenddateformat": "610",
                    "drugenddate": "202210",
                    "actiondrug": "1",
                    "drugadditional": "1",
                    "activesubstance": {
                        "activesubstancename": "UPADACITINIB"
                    },
                    "openfda": {
                        "application_number": [
                            "NDA211675"
                        ],
                        "brand_name": [
                            "RINVOQ"
                        ],
                        "generic_name": [
                            "UPADACITINIB"
                        ],
                        "manufacturer_name": [
                            "AbbVie Inc."
                        ],
                        "product_ndc": [
                            "0074-1043",
                            "0074-2306",
                            "0074-2310"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "route": [
                            "ORAL"
                        ],
                        "substance_name": [
                            "UPADACITINIB"
                        ],
                        "rxcui": [
                            "2196894",
                            "2196900",
                            "2590051",
                            "2590054",
                            "2596957",
                            "2596960"
                        ],
                        "spl_id": [
                            "b3ed4d84-05b2-41f8-9664-2e2fff13effc"
                        ],
                        "spl_set_id": [
                            "2966aec7-2ef0-923c-d8ff-fe1a957bf095"
                        ],
                        "package_ndc": [
                            "0074-2306-30",
                            "0074-2306-70",
                            "0074-2310-30",
                            "0074-2310-20",
                            "0074-1043-28",
                            "0074-1043-14"
                        ],
                        "nui": [
                            "N0000190858",
                            "N0000190857"
                        ],
                        "pharm_class_epc": [
                            "Janus Kinase Inhibitor [EPC]"
                        ],
                        "pharm_class_moa": [
                            "Janus Kinase Inhibitors [MoA]"
                        ],
                        "unii": [
                            "4RA0KN46E0"
                        ]
                    }
                },
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "AMIODARONE",
                    "drugseparatedosagenumb": "1",
                    "drugdosagetext": "STARTED APPROXIMATELY ONE WEEK AFTER STARTING RINVOQ IN OCT 2022 AND STOPPED APPROXIMATELY 1-2 WE...",
                    "drugadministrationroute": "048",
                    "drugindication": "Atrial fibrillation",
                    "drugstartdateformat": "602",
                    "drugstartdate": "2022",
                    "drugenddateformat": "602",
                    "drugenddate": "2022",
                    "actiondrug": "1",
                    "drugadditional": "1",
                    "activesubstance": {
                        "activesubstancename": "AMIODARONE"
                    }
                }
            ],
            "summary": {
                "narrativeincludeclinical": "CASE EVENT DATE: 20221001"
            }
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23328103",
        "primarysourcecountry": "US",
        "occurcountry": "US",
        "transmissiondateformat": "102",
        "transmissiondate": "20240109",
        "reporttype": "1",
        "serious": "2",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "2",
        "receivedateformat": "102",
        "receivedate": "20231221",
        "receiptdateformat": "102",
        "receiptdate": "20231221",
        "fulfillexpeditecriteria": "2",
        "companynumb": "US-BIOMARINAP-US-2023-154552",
        "primarysource": {
            "reportercountry": "US",
            "qualification": "5"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Nausea",
                    "reactionoutcome": "1"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "PALYNZIQ",
                    "drugbatchnumb": "not reported",
                    "drugauthorizationnumb": "761079",
                    "drugstructuredosagenumb": "10",
                    "drugstructuredosageunit": "003",
                    "drugdosagetext": "10 MILLIGRAM",
                    "drugdosageform": "Solution for injection",
                    "drugadministrationroute": "058",
                    "drugindication": "Product used for unknown indication",
                    "actiondrug": "4",
                    "activesubstance": {
                        "activesubstancename": "PEGVALIASE-PQPZ"
                    },
                    "openfda": {
                        "application_number": [
                            "BLA761079"
                        ],
                        "brand_name": [
                            "PALYNZIQ"
                        ],
                        "generic_name": [
                            "PEGVALIASE-PQPZ"
                        ],
                        "manufacturer_name": [
                            "BioMarin Pharmaceutical Inc."
                        ],
                        "product_ndc": [
                            "68135-058",
                            "68135-756",
                            "68135-673"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "route": [
                            "SUBCUTANEOUS"
                        ],
                        "substance_name": [
                            "PEGVALIASE"
                        ],
                        "rxcui": [
                            "2046365",
                            "2046370",
                            "2046374",
                            "2046376",
                            "2046379",
                            "2046380"
                        ],
                        "spl_id": [
                            "24831ce1-fc13-4fd1-9659-d95257ba807b"
                        ],
                        "spl_set_id": [
                            "6dba844a-db02-44f8-8593-ce497ed9406c"
                        ],
                        "package_ndc": [
                            "68135-058-89",
                            "68135-058-90",
                            "68135-756-19",
                            "68135-756-20",
                            "68135-673-39",
                            "68135-673-40",
                            "68135-673-45"
                        ],
                        "nui": [
                            "N0000193858",
                            "M0016545"
                        ],
                        "pharm_class_epc": [
                            "Phenylalanine Metabolizing Enzyme [EPC]"
                        ],
                        "pharm_class_cs": [
                            "Phenylalanine Ammonia-Lyase [CS]"
                        ],
                        "unii": [
                            "N6UAH27EUV"
                        ]
                    }
                }
            ]
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23328790",
        "primarysourcecountry": "IT",
        "occurcountry": "IT",
        "transmissiondateformat": "102",
        "transmissiondate": "20240110",
        "reporttype": "2",
        "serious": "1",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "1",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "2",
        "receivedateformat": "102",
        "receivedate": "20231221",
        "receiptdateformat": "102",
        "receiptdate": "20231221",
        "fulfillexpeditecriteria": "1",
        "companynumb": "IT-ABBVIE-5551820",
        "primarysource": {
            "reportercountry": "IT",
            "qualification": "5"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "patientonsetage": "76",
            "patientonsetageunit": "801",
            "patientsex": "2",
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Femoral neck fracture",
                    "reactionoutcome": "2"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Fall",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "CARBIDOPA\\LEVODOPA",
                    "drugbatchnumb": "Not Available",
                    "drugauthorizationnumb": "203952",
                    "drugseparatedosagenumb": "1",
                    "drugdosagetext": "DAILY DOSE (MG): 700; PUMP SETTING: MD: 4+3; CR: 2 (15H); ED: 0,5",
                    "drugdosageform": "Intestinal gel",
                    "drugadministrationroute": "050",
                    "drugindication": "Parkinson^s disease",
                    "actiondrug": "4",
                    "activesubstance": {
                        "activesubstancename": "CARBIDOPA\\LEVODOPA"
                    }
                },
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "CARBIDOPA\\LEVODOPA",
                    "drugauthorizationnumb": "203952",
                    "actiondrug": "4",
                    "activesubstance": {
                        "activesubstancename": "CARBIDOPA\\LEVODOPA"
                    }
                }
            ],
            "summary": {
                "narrativeincludeclinical": "CASE EVENT DATE: 20231205"
            }
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23329586",
        "primarysourcecountry": "KR",
        "occurcountry": "KR",
        "transmissiondateformat": "102",
        "transmissiondate": "20240109",
        "reporttype": "2",
        "serious": "1",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "1",
        "receivedateformat": "102",
        "receivedate": "20231222",
        "receiptdateformat": "102",
        "receiptdate": "20231222",
        "fulfillexpeditecriteria": "1",
        "companynumb": "KR-KYOWAKIRIN-2023KK019743",
        "duplicate": "1",
        "reportduplicate": {
            "duplicatesource": "KYOWAKIRIN",
            "duplicatenumb": "KR-KYOWAKIRIN-2023KK019743"
        },
        "primarysource": {
            "reportercountry": "KR",
            "qualification": "1"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "patientagegroup": "5",
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Febrile neutropenia",
                    "reactionoutcome": "1"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Febrile neutropenia",
                    "reactionoutcome": "6"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Neutropenia",
                    "reactionoutcome": "6"
                },
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Neutropenia",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "PEGFILGRASTIM",
                    "drugauthorizationnumb": "125031",
                    "drugdosagetext": "UNK",
                    "drugdosageform": "Solution for injection",
                    "drugadministrationroute": "065",
                    "drugindication": "Prophylaxis",
                    "actiondrug": "5",
                    "drugadditional": "3",
                    "activesubstance": {
                        "activesubstancename": "PEGFILGRASTIM"
                    },
                    "openfda": {
                        "application_number": [
                            "BLA125031",
                            "BLA761084"
                        ],
                        "brand_name": [
                            "NEULASTA",
                            "FYLNETRA"
                        ],
                        "generic_name": [
                            "PEGFILGRASTIM"
                        ],
                        "manufacturer_name": [
                            "Amgen Inc",
                            "Amneal Pharmaceuticals LLC"
                        ],
                        "product_ndc": [
                            "55513-190",
                            "55513-192",
                            "70121-1627"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "route": [
                            "SUBCUTANEOUS"
                        ],
                        "substance_name": [
                            "PEGFILGRASTIM"
                        ],
                        "rxcui": [
                            "727539",
                            "727542",
                            "2549331",
                            "2549333",
                            "2602781",
                            "2602787"
                        ],
                        "spl_id": [
                            "50374606-0a76-45df-8b19-8323cc511e87",
                            "b512ecac-1a1c-41ad-bbeb-f46cc90c1333"
                        ],
                        "spl_set_id": [
                            "fdfe5d72-6b80-435a-afa4-c5d74dd852ce",
                            "eeadd641-573d-47fe-897a-61006e5f9e03"
                        ],
                        "package_ndc": [
                            "55513-192-01",
                            "55513-190-01",
                            "70121-1627-1"
                        ],
                        "nui": [
                            "M0024696",
                            "N0000009451",
                            "N0000175666"
                        ],
                        "pharm_class_cs": [
                            "Granulocyte Colony-Stimulating Factor [CS]"
                        ],
                        "pharm_class_pe": [
                            "Increased Myeloid Cell Production [PE]"
                        ],
                        "pharm_class_epc": [
                            "Leukocyte Growth Factor [EPC]"
                        ],
                        "unii": [
                            "3A58010674"
                        ]
                    }
                }
            ]
        }
    },
    {
        "safetyreportversion": "1",
        "safetyreportid": "23330142",
        "primarysourcecountry": "DE",
        "occurcountry": "DE",
        "transmissiondateformat": "102",
        "transmissiondate": "20240109",
        "reporttype": "1",
        "serious": "1",
        "seriousnessdeath": "2",
        "seriousnesslifethreatening": "2",
        "seriousnesshospitalization": "2",
        "seriousnessdisabling": "2",
        "seriousnesscongenitalanomali": "2",
        "seriousnessother": "1",
        "receivedateformat": "102",
        "receivedate": "20231222",
        "receiptdateformat": "102",
        "receiptdate": "20231222",
        "fulfillexpeditecriteria": "1",
        "companynumb": "DE-SANOFI-01877586",
        "duplicate": "1",
        "reportduplicate": {
            "duplicatesource": "SANOFI",
            "duplicatenumb": "DE-SANOFI-01877586"
        },
        "primarysource": {
            "reportercountry": "DE",
            "qualification": "1"
        },
        "sender": {
            "sendertype": "2",
            "senderorganization": "FDA-Public Use"
        },
        "receiver": {
            "receivertype": "6",
            "receiverorganization": "FDA"
        },
        "patient": {
            "patientonsetage": "44",
            "patientonsetageunit": "801",
            "patientagegroup": "5",
            "patientsex": "2",
            "reaction": [
                {
                    "reactionmeddraversionpt": "26.1",
                    "reactionmeddrapt": "Erysipelas",
                    "reactionoutcome": "6"
                }
            ],
            "drug": [
                {
                    "drugcharacterization": "1",
                    "medicinalproduct": "AUBAGIO",
                    "drugauthorizationnumb": "202992",
                    "drugdosagetext": "UNK",
                    "drugdosageform": "Film-coated tablet",
                    "actiondrug": "5",
                    "drugadditional": "3",
                    "activesubstance": {
                        "activesubstancename": "TERIFLUNOMIDE"
                    },
                    "openfda": {
                        "application_number": [
                            "NDA202992"
                        ],
                        "brand_name": [
                            "AUBAGIO"
                        ],
                        "generic_name": [
                            "TERIFLUNOMIDE"
                        ],
                        "manufacturer_name": [
                            "Genzyme Corporation"
                        ],
                        "product_ndc": [
                            "58468-0210",
                            "58468-0211"
                        ],
                        "product_type": [
                            "HUMAN PRESCRIPTION DRUG"
                        ],
                        "route": [
                            "ORAL"
                        ],
                        "substance_name": [
                            "TERIFLUNOMIDE"
                        ],
                        "rxcui": [
                            "1310525",
                            "1310531",
                            "1310533",
                            "1310535"
                        ],
                        "spl_id": [
                            "6376f9aa-fb14-4e8d-988a-a9d0bf1a530c"
                        ],
                        "spl_set_id": [
                            "4650d12c-b9c8-4525-b07f-a2d773eca155"
                        ],
                        "package_ndc": [
                            "58468-0211-1",
                            "58468-0211-2",
                            "58468-0211-4",
                            "58468-0211-3",
                            "58468-0210-2",
                            "58468-0210-1",
                            "58468-0210-4",
                            "58468-0210-3"
                        ],
                        "nui": [
                            "N0000185502",
                            "N0000185501"
                        ],
                        "pharm_class_epc": [
                            "Pyrimidine Synthesis Inhibitor [EPC]"
                        ],
                        "pharm_class_moa": [
                            "Dihydroorotate Dehydrogenase Inhibitors [MoA]"
                        ],
                        "unii": [
                            "1C058IKG3B"
                        ]
                    }
                }
            ]
        }
    }
]" Given the [RESULTS] above highlights which ones could be adverse drug events